Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down on Analyst Downgrade

Xenon Pharmaceuticals Inc. (NASDAQ:XENE)’s share price gapped down before the market opened on Friday after Royal Bank Of Canada lowered their price target on the stock from $81.00 to $70.00. The stock had previously closed at $57.35, but opened at $44.02. Royal Bank Of Canada currently has an outperform rating on the stock. Xenon Pharmaceuticals shares last traded at $40.6950, with a volume of 4,216,082 shares.

Several other research firms have also commented on XENE. Needham & Company LLC lowered their price objective on Xenon Pharmaceuticals from $78.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday. Wall Street Zen upgraded shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Wedbush decreased their price objective on shares of Xenon Pharmaceuticals from $71.00 to $55.00 and set an “outperform” rating for the company in a research report on Friday. JPMorgan Chase & Co. increased their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Finally, Wells Fargo & Company dropped their target price on Xenon Pharmaceuticals from $69.00 to $64.00 and set an “overweight” rating on the stock in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $70.93.

Insider Activity

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the completion of the sale, the director directly owned 1,870 shares in the company, valued at approximately $119,792.20. The trade was a 84.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Kenney sold 7,068 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $60.25, for a total transaction of $425,847.00. Following the sale, the insider directly owned 2 shares of the company’s stock, valued at $120.50. The trade was a 99.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals News Summary

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Xenon submitted a New Drug Application to the FDA for azetukalner in focal seizures, a major regulatory milestone that could support the drug’s first potential commercial indication. Xenon NDA submission announcement
• Positive Sentiment: Despite reducing their valuation assumptions, Wedbush, Robert W. Baird, and Needham retained bullish ratings of “outperform” or “buy.” Their revised targets still indicate substantial potential upside from the current trading level: $55, $90, and $60, respectively. Analyst actions on Xenon Pharmaceuticals
• Neutral Sentiment: The FDA filing advances azetukalner’s focal-seizure program, while the company’s broader psychiatry strategy is being reassessed following reported adverse events involving mental and nervous-system symptoms. Xenon clinical program update transcript
• Negative Sentiment: Xenon temporarily halted new enrollment in depression and bipolar-disorder trials after adverse events were reported. The pause raises safety, timing, and commercial-viability risks for azetukalner’s psychiatric opportunity and prompted the sharp decline in XENE shares. Reuters report on Xenon trial pause
• Negative Sentiment: Analysts lowered their price targets substantially, signaling reduced confidence in the company’s near-term risk-reward profile even though their overall ratings remain positive. Xenon stock market update

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. grew its holdings in Xenon Pharmaceuticals by 450.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 900 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter worth about $53,000. Clearstead Advisors LLC increased its position in shares of Xenon Pharmaceuticals by 214.8% during the fourth quarter. Clearstead Advisors LLC now owns 1,215 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 829 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $55,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter valued at $57,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Stock Down 28.0%

The firm has a market cap of $3.99 billion, a price-to-earnings ratio of -8.67 and a beta of 0.61. The company’s 50-day moving average price is $62.70 and its 200-day moving average price is $58.07.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter in the previous year, the business earned ($1.07) EPS. On average, sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc (NASDAQ:XENE) is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its expertise in ion channels, which regulate the electrical activity of nerve cells, to discover and advance potential treatments for conditions with significant unmet medical needs.

Xenon’s leading investigational product is azetukalner (XEN1101), an oral, small-molecule potassium-channel opener being studied in epilepsy, including focal-onset seizures, and major depressive disorder.